Non Alcoholic Fatty Liver Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Non Alcoholic Fatty Liver Disease stocks.

Non Alcoholic Fatty Liver Disease Stocks Recent News

Date Stock Title
May 16 SGMT Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
May 16 SGMT Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
May 15 VKTX Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
May 15 VKTX Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
May 15 GALT Galectin Therapeutics GAAP EPS of -$0.19
May 15 SGMT Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 15 GALT Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
May 15 BLTE Belite Bio, Inc 2024 Q1 - Results - Earnings Call Presentation
May 15 BLTE Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
May 14 BLTE Belite Bio reports Q1 results
May 14 VKTX How Is The Market Feeling About Viking Therapeutics?
May 14 PLRX Pliant reports phase 2 data on idiopathic pulmonary fibrosis asset bexotegrast
May 14 BLTE Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
May 14 PLRX Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
May 14 BLTE Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
May 13 IVA Why Is Inventiva's Stock Trading Higher on Monday?
May 13 VKTX How Viking Therapeutics Stock Could 30x
May 13 TERN Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections
May 13 TERN Terns Pharmaceuticals GAAP EPS of -$0.30
May 13 VKTX Is Viking Therapeutics the Best Biotech Stock for You?
Non Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver, causing inflammation and damage. It is the most common form of liver disease in the United States, affecting up to 25% of the population. NAFLD is closely linked to obesity, diabetes, and high cholesterol, and can lead to serious complications such as cirrhosis and liver cancer. Treatment typically involves lifestyle changes such as weight loss, exercise, and a healthy diet.

Browse All Tags